Tazarotene 0.1% gel for refractory mycosis fungoides lessions: An open-label pilot study

Journal of the American Academy of Dermatology

Volumn 50, Issue 4, 2004, Pages 600-607

  Apisarnthanarax, Narin ^a,b   Talpur, Rakhshandra ^a,b   Ward, Staci ^a,b   Ni, Xiao ^a,b   Kim, Hyung Woo ^a,b   Duvic, Madeleine ^a,b,c  

^a M D Anderson Cancer Center ^*

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD45 ANTIGEN; CD45RO ANTIBODY; CD8 ANTIBODY; CD8 ANTIGEN; STEROID; TAZAROTENE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; ARTICLE; BURNING SENSATION; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; ERYTHEMA; GEL; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MYCOSIS FUNGOIDES; PILOT STUDY; PRIORITY JOURNAL; RELAPSE; REMISSION; SCORING SYSTEM; SKIN ABRASION; SKIN BIOPSY; SKIN IRRITATION;

EID: 1642393756     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2003.09.005     Document Type: Article

References (26)

1. Kim YH, Hoppe RT. Mycosis fungoides and the Sezary syndrome. Semin Oncol 1999;26:276-89.
2. Kim YH, Jensen RA, Watanabe GL, Varghese A, Hoppe RT. Clinical stage IA (limited patch and plaque) mycosis fungoides: a long-term outcome analysis. Arch Dermatol 1996;132:1309-13.
3. Kim YH, Chow S, Varghese A, Hoppe RT. Clinical characteristics and long-term outcome of patients with generalized patch or plaque (T2) mycosis fungoides. Arch Dermatol 1999;135:26-32.
4. Bunn PA Jr, Hoffman SJ, Norris D, Golitz LE, Aeling JL. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and Sezary syndrome). Ann Intern Med 1994;121:592-602.
5. Apisarnthanarax N, Duvic M. CTCL: new immunomodulators. Dermatol Clin 2001;19:737-48.
6. Apisarnthanarax N, Duvic M. Therapy options in cutaneous T-cell lymphoma. Expert Rev Anticancer Ther 2001;1:403-20.
7. Apisarnthanarax N, Duvic M. Treatment of cutaneous T cell lymphoma: current status and future directions. Am J Clin Dermatol 2002;3:193-215.
8. Johnson A, Chandraratna RAS. Novel retinoids with receptor selectivity and functional selectivity. Br J Dermatol 1999; 140(Suppl):S12-7.
9. Weinstein GD, Krueger GG, Lowe NJ, Duvic M, Friedman DJ, Jegasothy BV, et al. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy and duration of therapeutic effect. J Am Acad Dermatol 1997; 37:85-92.
10. Shalita AR, Chalker DK, Griffith RF, Herbert AA, Hickman JG, Maloney JM, et al. Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehicle controlled study. Cutis 1999;63:349-54.
11. Peris K. Preliminary observations on the use of topical tazarotene to treat basal-cell carcinoma. N Engl J Med 1999;341:1767-8.
12. Sefton J, Kligman AM, Kopper SC, Lue JC, Gibson JR. Photodamage pilot study: a double-blind, vehicle controlled study to assess the efficacy and safety of tazarotene 0.1% gel. J Am Acad Dermatol 2000;43:656-63.
13. Breneman D, Duvic M, Kuzel T, Yocum R, Truglia J, Stevens V. Phase I and II trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol 2002;138:325-32.
14. Heald P, Mehlmauer M, Martin A, Olsen E, Worldwide Bexarotene Study Group, Crowley C, et al. The benefits of topical bexarotene (Targretin) in patients with refractory or persistent early stage CTCL [abstract]. J Invest Dermatol 2000;114:840.
15. Duvic M, Martin A, Kim Y, Olsen E, Wood G, Crowley CA, et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001;137:581-93.
16. Duvic M, Hymes K, Heald P, Martin AG, Myskowski P, Crowley C, Breneman D, Martin AG, Myskowski P, et al. Bexarotene is effective and safe for the treatment of refractory advanced stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001;19:2456-71.
17. Conover WJ. Practical non-parametric statistics. 2nd ed. New York: Wiley; 1980.
18. Vonesh EF, Chinchilli VM. Linear and non-linear models for analysis of repeated measures. New York: Marcel Dekker; 1977.
19. Duvic M, Nagpal S, Asano AT, Chandraratna RAS. Molecular mechanisms of tazarotene action in psoriasis. J Am Acad Dermatol 1997;37(Suppl):S18-24.
20. Duvic M, Asano AT, Hager C, Mays S. The pathogenesis of psoriasis and the mechanism of action of tazarotene. J Am Acad Dermatol 1998; 39/Suppl):S129-33.
21. Duvic M, Ni X, Talpur R, Herne K, Schulz C, Sui D, et al. Tazarotene-induced gene 3 is suppressed in basal cell carcinomas and reversed in vivo by tazarotene application. J Invest Dermatol 2003;121:902-9.
22. + cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune response. Clin Cancer Res 2001;7: 2682-92.
23. Kessler JF, Jones SE, Levine N, Lynch PJ, Booth AR. Isotretinoin and cutaneous helper-T-cell lymphoma (mycosis fungoides). Arch Dermatol 1987;123:201-4.
24. Lebwohl M, Poulin Y. Tazarotene in combination with topical corticosteroids. J Am Acad Dermatol 1998;39(Suppl):S139-43.
25. Hoppe RT, Medeiros LJ, Warnke RA, Wood GS. CD8-positive tumor-infiltrating lymphocytes influence the long-term survival of patients with mycosis fungoides. J Am Acad Dermatol 1995; 32:448-53.
26. Zhang C, Hazarika P, Ni X, Weidner DA, Duvic M. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma (CTCL) cells: relevance to mechanism of therapeutic action. Clin Cancer Res 2002;8:1234-40.